Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30125933 | 0.91 | CYP19A1 (0.53) | CYP19A1SCDHSD17B10SIGMAR1VCAM1 | |
| SCHEMBL10002964 | 0.91 | CYP19A1 (0.53) | CYP19A1SCDHSD17B10SIGMAR1VCAM1 | |
| SCHEMBL4377013 | 0.82 | CYP19A1 (0.49) | CYP19A1SCDSIGMAR1ALDH1A1KDM4E | |
| SCHEMBL13419634 | 0.82 | S1PR4 (0.49) | CYP19A1SIGMAR1ALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL445361 | 0.81 | CYP19A1 (0.45) | CYP19A1SIGMAR1SLC6A2SLC6A4HTR3A | |
| SCHEMBL4362951 | 0.80 | CHRNA3 (0.46) | SCDSLC6A2SLC6A4 | |
| SCHEMBL4362945 | 0.80 | CHRNA3 (0.46) | SCDSLC6A2SLC6A4 | |
| SCHEMBL4367645 | 0.80 | HRH3 (0.52) | CYP19A1SCDSIGMAR1ALDH1A1SLC6A4 | |
| SCHEMBL2564892 | 0.80 | MAPT (0.53) | CYP19A1HSD17B10SIGMAR1ALDH1A1LMNA | |
| SCHEMBL4500135 | 0.79 | SLC6A4 (0.52) | MAP2K1SLC6A2SLC6A4HTR3AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | CYP19A1 29/4885SCD 1618/4885MAP2K1 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.